December 18, 2020 Substance Use Disorder Treatment Webinar Series Session 5:
Use of Buprenorphine in OUD Part 2

POST-WEBINAR SURVEY

Please take a few moments to complete the following post-webinar survey to help us assess your experience with this webinar series.

Question Title

* 1. Personal Information

First Name

Last Name

Credential

Question Title

* 2. Organization

Question Title

* 3. Please choose your role:

Provider (MD, DO, PA-C, NP, etc.)

Nurse Care Manager/Care Coordinator

Social Worker Care Manager/Behavioral Health Specialist

Pharmacist

Other Clinical (CMA, RMA, etc.)

Non-Clinical (Practice Manager, Support Staff, etc.)

Leadership

Other (please specify)

Question Title

* 4. **On a scale of 1-5 please rate the topic of this session: Use of Buprenorphine in Opioid Use Disorders Part Two.**

1-Very dissatisfied

2-Dissatisfied

3-Neutral

4-Satisfied

5-Very Satisfied

1-Very dissatisfied

2-Dissatisfied

3-Neutral

4-Satisfied

5-Very Satisfied

Question Title

* 5. If you scored the above question at a 4 or 5, please give examples of what was most helpful.

Question Title

* 6. If you scored the above question at a 1 or 2, please tell us more.

Question Title

* 7. After attending this webinar, please rate your change in confidence with managing individuals with OUD.

1-Not at all Confident

2-Somewhat Confident

3-Confident

4-Very Confident

1-Not at all Confident

2-Somewhat Confident

3-Confident

4-Very Confident

Question Title

* 8. After attending this session, what would be helpful to learn about in future sessions?

Question Title

* 9. I felt the presentations were free of commercial bias.

Yes

Question Title

* 10. If you answered no to question 9, please describe bias.

Question Title

* 11. Were disclosures made available to you?

Yes

December 18, 2020 Substance Use Disorder Treatment Webinar Series Session 5:
Use of Buprenorphine in OUD Part 2

POST-WEBINAR SURVEY

Question Title

* 1. Personal Information

Question Title

* 2. Organization

Question Title

* 3. Please choose your role:

Question Title

* 4. **On a scale of 1-5 please rate the topic of this session: Use of Buprenorphine in Opioid Use Disorders Part Two.**

Question Title

* 5. If you scored the above question at a 4 or 5, please give examples of what was most helpful.

Question Title

* 6. If you scored the above question at a 1 or 2, please tell us more.

Question Title

* 7. After attending this webinar, please rate your change in confidence with managing individuals with OUD.

Question Title

* 8. After attending this session, what would be helpful to learn about in future sessions?

Question Title

* 9. I felt the presentations were free of commercial bias.

Question Title

* 10. If you answered no to question 9, please describe bias.

Question Title

* 11. Were disclosures made available to you?

Question Title

* 12. What new abilities/strategies have you gained from this session?

Question Title

* 13. Other Comments:

Question Title

* 1. Personal Information

Question Title

* 2. Organization

Question Title

* 3. Please choose your role:

Question Title

* 4. On a scale of 1-5 please rate the topic of this session: Use of Buprenorphine in Opioid Use Disorders Part Two.

Question Title

* 5. If you scored the above question at a 4 or 5, please give examples of what was most helpful.

Question Title

* 6. If you scored the above question at a 1 or 2, please tell us more.

Question Title

* 7. After attending this webinar, please rate your change in confidence with managing individuals with OUD.

Question Title

* 8. After attending this session, what would be helpful to learn about in future sessions?

Question Title

* 9. I felt the presentations were free of commercial bias.

Question Title

* 10. If you answered no to question 9, please describe bias.

Question Title

* 11. Were disclosures made available to you?

Question Title

* 12. What new abilities/strategies have you gained from this session?

Question Title

* 13. Other Comments:

* 4. **On a scale of 1-5 please rate the topic of this session: Use of Buprenorphine in Opioid Use Disorders Part Two.**